FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Nutrition & Health News

Special Report: Bone Health Supplementation Moves Beyond Dairy

22 May 2017 --- Bone health is becoming an increasingly researched topic, particularly as populations around the globe are becoming more aged. Consuming dairy products for strong bones has long been encouraged by governments and parents alike. However, as consumer preferences change, there is a growing need for non-dairy supplementation that can improve bone density. According to Innova Market Insights data, the number of product launches featuring bone health claims rose drastically from 364 in 2015, to 571 in 2016. NutritionInsight looks at some of the most recent bone health related product launches and studies.

Business News

Scientists Urge US Government to Meet Compliance Deadline for Nutrition Labels

22 May 2017 --- As US food industry groups continue to urge the government to delay the July 2018 compliance date for the updated nutrition facts label, consumer advocacy group and non-profit watchdog Center for Science in the Public Interest (CSPI) claims that more than 40 scientists and researchers from across the country are calling for the date to stand.

Business News

No Such Thing as “Healthy Obesity”: Study

22 May 2017 --- “Healthy” obese people are still at higher risk of heart failure or stroke than the general population, according to research by scientists at the University of Birmingham. The results indicate that the concept of “healthy obesity” – a condition characterized by having normal markers of metabolic health despite a body mass index (BMI) of 30 or more – is, in fact, a myth.

Nutrition & Health News

Neuroimaging Highlights Role of Omega 3 in Preventing Cognitive Decline

22 May 2017 --- Research involving neuroimaging has shown that people with higher omega 3 levels have increased blood flow in regions of the brain associated with memory and learning, according to a report in the Journal of Alzheimer’s Disease. With the incidence of Alzheimer’s disease (AD) expected to triple in the coming decades, interest in dietary approaches for the prevention of cognitive decline has increased. In particular, the omega 3 fatty acids have shown anti-amyloid, anti-tau and anti-inflammatory actions in the brains of animals. 

 

Business News

Grilling or Microwaving Best Ways to Preserve Nutritional Value of Mushrooms

22 May 2017 --- A study by Spanish researchers has shown that microwaving and grilling are the best way to prepare mushrooms in terms of maintaining their nutritional profile. Mushrooms are considered valuable health foods, since they have a significant amount of dietary fiber and are poor in calories and fat. Moreover, they have a good protein content (20-30% of dry matter) which includes most of the essential amino acids.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html